Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Astrazeneca Plc (AZN.LN)

Astrazeneca Plc (AZN.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 211,411,611
  • Shares Outstanding, K 1,550,848
  • Annual Sales, $ 58,739 M
  • Annual Income, $ 10,225 M
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales 4.77
  • Price/Cash Flow 20.25
  • Price/Book 6.04
  • Price/Earnings ttm 27.77
  • Earnings Per Share ttm 6.64
  • Most Recent Earnings $1.97 on 04/29/26
  • Next Earnings Date N/A
  • Annual Dividend & Yield (Fwd) 3.19 (1.73%)
  • Most Recent Dividend 1.595 on 02/19/26
  • Sector N/A
  • INDUSTRY GROUPING N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
12,356.000 +10.62%
on 04/23/26
15,118.002 -9.59%
on 04/17/26
-1,097.770 (-7.43%)
since 04/15/26
3-Month
12,356.000 +10.62%
on 04/23/26
15,732.000 -13.12%
on 02/18/26
-1,455.164 (-9.62%)
since 02/13/26
52-Week
10,103.000 +35.29%
on 07/01/25
15,732.000 -13.12%
on 02/18/26
+3,526.232 (+34.77%)
since 05/15/25

Most Recent Stories

More News
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer Business Wire - Fri May 15, 8:52PM CDT

Approved for use before surgery based on DESTINY-Breast11 Phase III trial Approved for use following surgery based on DESTINY-Breast05 Phase III trial...

AZN : 181.58 (-1.83%)
AZN.LN : 13,668.232 (-0.52%)
Perioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial Business Wire - Thu May 14, 6:00AM CDT

Perioperative IMFINZI plus IMJUDO® (tremelimumab-actl) and neoadjuvant EV showed a statistically significant and clinically meaningful improvement in event-free survival and a favorable trend for overall...

AZN : 181.58 (-1.83%)
AZN.LN : 13,668.232 (-0.52%)
TRUQAP® (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer Business Wire - Thu Apr 30, 8:42PM CDT

ODAC overwhelming majority voted that TRUQAP plus abiraterone and ADT demonstrated a favorable benefit risk profile for patients based on the CAPItello-281 Phase III trial results ...

AZN : 181.58 (-1.83%)
AZN.LN : 13,668.232 (-0.52%)
AstraZeneca results: Q1 2026 Business Wire - Wed Apr 29, 6:00AM CDT

Strong revenue growth and positive readouts from high-value NMEs reinforce confidence in 2030 ambition

AZN : 181.58 (-1.83%)
AZN.LN : 13,668.232 (-0.52%)
Trader at NYSE by Orhan Akkurt via Shutterstock
Stock Index Futures Gain on Tech Boost Ahead of Fed Decision and Megacap Earnings Barchart - Wed Apr 29, 5:33AM CDT

June S&P 500 E-Mini futures (ESM26) are up +0.14%, and June Nasdaq 100 E-Mini futures (NQM26) are up +0.27% this morning, buoyed by gains in technology stocks, while investors await the Federal Reserve’s...

GOOGL : 396.78 (-1.07%)
ADS.D.DX : 146.450 (-0.48%)
BE : 275.95 (-9.05%)
SNDK : 1,407.61 (+1.80%)
F : 13.40 (-7.46%)
ESM26 : 7,432.25s (-1.24%)
MSFT : 421.92 (+3.05%)
QCOM : 201.49 (+0.70%)
STX : 795.47 (-1.15%)
V : 325.75 (+1.00%)
WDC : 482.02 (-1.46%)
AZN.LN : 13,668.232 (-0.52%)
BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older Business Wire - Tue Apr 28, 6:00AM CDT

Approval based on KALOS and LOGOS Phase III trials demonstrating statistically significant and clinically meaningful benefits of AstraZeneca’s single-inhaler fixed-dose triple therapy compared with inhaled...

AZN : 181.58 (-1.83%)
AZN.LN : 13,668.232 (-0.52%)
SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus Business Wire - Mon Apr 27, 6:00AM CDT

First-in-class SAPHNELO Pen now offers greater flexibility and convenience, reaching a wider group of patients

AZN : 181.58 (-1.83%)
AZN.LN : 13,668.232 (-0.52%)
Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD Business Wire - Mon Apr 20, 6:00AM CDT

Third positive pivotal Phase III clinical trial of AstraZeneca’s IL-33-targeting biologic further demonstrates its benefits in COPD

AZN : 181.58 (-1.83%)
AZN.LN : 13,668.232 (-0.52%)
IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer Business Wire - Thu Apr 2, 6:00AM CDT

IMFINZI plus IMJUDO combined with lenvatinib and TACE demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in embolization-eligible unresectable liver...

AZN : 181.58 (-1.83%)
AZN.LN : 13,668.232 (-0.52%)
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD Business Wire - Fri Mar 27, 6:00AM CDT

First-ever IL-33-targeting biologic to demonstrate statistically significant and highly clinically meaningful reductions in COPD exacerbations in two replicate Phase III clinical trials

AZN : 181.58 (-1.83%)
AZN.LN : 13,668.232 (-0.52%)
More news for this symbol

Barchart Technical Opinion

Weak sell

The Barchart Technical Opinion rating is a 8% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Key Turning Points

3rd Resistance Point 14,228.155
2nd Resistance Point 14,060.077
1st Resistance Point 13,864.155
Last Price 13,668.232
1st Support Level 13,500.155
2nd Support Level 13,332.077
3rd Support Level 13,136.155

See More

52-Week High 15,732.000
Last Price 13,668.232
Fibonacci 61.8% 13,581.722
Fibonacci 50% 12,917.500
Fibonacci 38.2% 12,253.277
52-Week Low 10,103.000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.